Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
March 27 2019 - 7:30AM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a
leader in developing novel, controllable cellular immunotherapies
for cancers and orphan inherited blood disorders, today announced
participation in the Jefferies 6th Annual IO Cell Therapy Summit
taking place in Boston. Bellicum’s President & CEO Rick Fair
and Head of Research, Aaron Foster, Ph.D., will provide an overview
of the company and its development programs during a fireside chat
on April 5, 2019 at 9:10 a.m. EDT.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T®
candidate, BPX-601, is designed to be a more efficacious CAR-T cell
product capable of overriding key immune inhibitory mechanisms.
Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T
cell therapy that has shown promising clinical trial results in
reducing leukemia relapse after a stem cell transplant. More
information can be found at www.bellicum.com.
Contacts:
InvestorsRobert H. UhlManaging DirectorWestwicke
IR858-356-5932Robert.uhl@westwicke.com
MediaJim Heins Senior Vice President Westwicke PR 203-682-8251
james.heins@icrinc.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Sep 2023 to Sep 2024